Price Alert

Rhythm Pharmaceuticals In... (RYTM)

NASDAQ: RYTM · Real-Time Price · USD

96.48

-1.38 (-1.41%)

At close: Aug 14, 2025, 3:59 PM

96.48

0.00%

Pre-market: Aug 15, 2025, 08:45 AM EDT

Rhythm Pharmaceuticals Statistics

Share Statistics

Rhythm Pharmaceuticals has 66.42M shares outstanding. The number of shares has increased by 4.07% in one year.

Shares Outstanding	66.42M
Shares Change (YoY)	4.07%
Shares Change (QoQ)	0.63%
Owned by Institutions (%)	99.99%
Shares Floating	60.75M
Failed to Deliver (FTD) Shares	2,033
FTD / Avg. Volume	0.29%

Short Selling Information

The latest short interest is 4.79M, so 7.26% of the outstanding shares have been sold short.

Short Interest	4.79M
Short % of Shares Out	7.26%
Short % of Float	9.33%
Short Ratio (days to cover)	3.48

Valuation Ratios

The PE ratio is -13.1 and the forward PE ratio is -45.66. Rhythm Pharmaceuticals's PEG ratio is -0.42.

PE Ratio	-13.1
Forward PE	-45.66
PS Ratio	26.24
Forward PS	21
PB Ratio	20.75
P/FCF Ratio	-29.98
PEG Ratio	-0.42

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Rhythm Pharmaceuticals.

EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 3.24, with a Debt / Equity ratio of 0.02.

Current Ratio	3.24
Quick Ratio	3.08
Debt / Equity	0.02
Debt / EBITDA	-0.02
Debt / FCF	-0.03
Interest Coverage	-12.89

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity	n/a
Return on Assets	n/a
Return on Invested Capital	n/a
Revenue Per Employee	$459.81K
Profits Per Employee	$-920.86K
Employee Count	283
Asset Turnover	0.33
Inventory Turnover	0.71

Taxes

Income Tax	346K
Effective Tax Rate	-0.13%

Stock Price Statistics

The stock price has increased by 112.05% in the last 52 weeks. The beta is 2.39, so Rhythm Pharmaceuticals's price volatility has been higher than the market average.

Beta	2.39
52-Week Price Change	112.05%
50-Day Moving Average	75.29
200-Day Moving Average	61.64
Relative Strength Index (RSI)	69.5
Average Volume (20 Days)	712,630

Income Statement

In the last 12 months, Rhythm Pharmaceuticals had revenue of 130.13M and earned -260.6M in profits. Earnings per share was -4.21.

Revenue	130.13M
Gross Profit	116.76M
Operating Income	-265.5M
Net Income	-260.6M
EBITDA	-238.09M
EBIT	-239.65M
Earnings Per Share (EPS)	-4.21

Full Income Statement

Balance Sheet

The company has 89.14M in cash and 3.94M in debt, giving a net cash position of 85.2M.

Cash & Cash Equivalents	89.14M
Total Debt	3.94M
Net Cash	85.2M
Retained Earnings	-1.16B
Total Assets	372.73M
Working Capital	231.22M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -113.88M and capital expenditures 0, giving a free cash flow of -113.88M.

Operating Cash Flow	-113.88M
Capital Expenditures	n/a
Free Cash Flow	-113.88M
FCF Per Share	-1.87

Full Cash Flow Statement

Margins

Gross margin is 89.73%, with operating and profit margins of -204.04% and -200.27%.

Gross Margin	89.73%
Operating Margin	-204.04%
Pretax Margin	-200%
Profit Margin	-200.27%
EBITDA Margin	-182.97%
EBIT Margin	-204.04%
FCF Margin	-87.51%

Dividends & Yields

RYTM does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Analyst Forecast

The average price target for RYTM is $103.5, which is 9.7% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$103.5
Price Target Difference	9.7%
Analyst Consensus	Strong Buy
Analyst Count	13

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Scores

Altman Z-Score	10.33
Piotroski F-Score	3